STOCK-BASED COMPENSATION (Tables)

9 Months Ended

12 Months Ended

Sep. 30, 2021

Dec. 31, 2020

Share-based Payment Arrangement [Abstract]

Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions

The following table provides the weighted average assumptions used in determining the fair value of the stock option awards granted during the nine-month periods ended September 30, 2021 and 2020.

	September 30, 2021			September 30, 2020
	(unaudited)
Risk-free interest rate		0.78	%		0.79	%
Expected life		6.0 years			6.6 years
Expected volatility		134.79	%		122.24	%
Dividend yield		-			-

The following table provides the weighted average assumptions used in determining the fair value of the stock options granted during the years ended December 31, 2020 and December 31, 2019.

	December 31, 2020			December 31, 2019
Risk-free interest rate		0.75	%		2.34	%
Expected life		6.5 years			5.9 years
Expected volatility		123.71	%		128.58	%
Dividend yield		-			-

SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2021		2020		2021		2020
	(unaudited)				(unaudited)
Cost of revenue	$	52	$	60	$	154	$	187
Sales and marketing		76		39		201		136
Research and development		24		30		83		99
General and administrative*		325		434		876		959
Total stock compensation expense	$	477	$	563	$	1,314	$	1,381

* Includes ESPP expense

Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award

Stock-based compensation for the years ended December 31, 2020 and 2019 is as follows:

	2020		2019
RSUs and restricted stock	$	176	$	243
Performance-based awards		265		-
Common stock awards		116		-
Options		1,630		722
Total stock-based compensation expense	$	2,187	$	965

Schedule of Stock Option Activity

A summary of stock option and SARs activity for the year ended December 31, 2020, and changes during such year, is presented below:

				Weighted-		Weighted-Average
				Average		Remaining		Aggregate
				Grant		Contractual		Intrinsic
	Shares			Price		Period (in years)		Value
Outstanding at January 1, 2020		415,678		$	12.50		8.45	$	-
Granted		525,550			6.24		9.39		-
Exercised		-
Forfeited or expired		(92,409	)		11.18				-
Outstanding at December 31, 2020		848,819			8.76		8.59		-
Exercisable at December 31, 2020		361,501			11.81		7.77		-
Vested and expected to vest		659,465			9.48		8.39		-

Schedule of Non Vested Option Activity

A summary of the status of the Company’s non-vested options for the year ended December 31, 2020, and changes during such year, is presented below:

	Shares			Weighted- Average Grant Date Fair Value
Nonvested at January 1, 2020		213,472		$	8.80
Granted		525,550			5.36
Vested		(197,998	)		7.34
Forfeited		(53,706	)		7.86
Nonvested at December 31, 2020		487,318		$	5.81

Schedule of Share-Based Compensation, Restricted Stock and Restricted Stock Units Activity

A summary of the Company’s non-vested shares of restricted stock and restricted stock units for the year ended December 31, 2020, and changes during such year, is presented below:

				Weighted-		Average
				Average		Remaining		Aggregate
				Grant Date		Vesting		Intrinsic
	Shares			Fair Value		Period (in years)		Value
Nonvested at January 1, 2020		49,366		$	10.04		1.11	$	246,830
Granted		236,321			3.43		-		-
Vested		(43,976	)		9.52		-		-
Forfeited		(2,254	)		10.10		-		-
Nonvested at December 31, 2020		239,457		$	3.61		1.75	$	751,895